Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2001 Apr 9;11(7):895-8.

The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase--GW311616A a development candidate.

Author information

1
Medicinal Chemistry 2, GlaxoWellcome Medicines Research Centre, Stevenage, UK. sjfm5947@glaxowellcome.co.uk

Abstract

The discovery of a potent intracellular inhibitor of human neutrophil elastase which is orally active and has a long duration of action is described. The pharmacodynamic and pharmacokinetic properties of a trans-lactam development candidate, GW311616A, are described.

PMID:
11294386
DOI:
10.1016/s0960-894x(01)00078-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center